Compare · NTRA vs SQL
NTRA vs SQL
Side-by-side comparison of Natera Inc. (NTRA) and SeqLL Inc. (SQL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and SQL operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA carries a market cap of $44.78B.
- NTRA has hit the wire 32 times in the past 4 weeks while SQL has been quiet.
- NTRA has more recent analyst coverage (25 ratings vs 1 for SQL).
- Company
- Natera Inc.
- SeqLL Inc.
- Price
- -
- -
- Market cap
- $44.78B
- -
- 1M return
- -20.58%
- -
- 1Y return
- +55.40%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2021
- News (4w)
- 32
- 0
- Recent ratings
- 25
- 1
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest NTRA
- Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.
- SEC Form 10-Q filed by Natera Inc.
- Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Natera Announces Leadership Transition
- Natera Reports Third Quarter 2026 Financial Results
- SEC Form SCHEDULE 13G filed by Natera Inc.
- Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $299,214 worth of shares (748 units at $400.02) as part of a pre-agreed trading plan, decreasing direct ownership by 0.04% to 2,116,928 units (SEC Form 4) (for tax liability)
- CO-FOUNDER Sheena Jonathan sold $44,797 worth of shares (112 units at $399.97) as part of a pre-agreed trading plan, decreasing direct ownership by 0.05% to 217,574 units (SEC Form 4) to satisfy withholding obligation
- CEO AND PRESIDENT Chapman Steven Leonard sold $1,565,239 worth of shares (3,801 units at $411.80) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 87,431 units (SEC Form 4) to satisfy tax liability
Latest SQL
- Atlantic International Corp. Acquires Lyneer Staffing Solutions
- SEC Form EFFECT filed by SeqLL Inc.
- SEC Form S-1/A filed by SeqLL Inc. (Amendment)
- SEC Form S-1/A filed by SeqLL Inc. (Amendment)
- SEC Form S-1/A filed by SeqLL Inc. (Amendment)
- SEC Form S-1/A filed by SeqLL Inc. (Amendment)
- SeqLL Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form S-1/A filed by SeqLL Inc. (Amendment)
- SEC Form S-1/A filed by SeqLL Inc. (Amendment)
- SEC Form 10-Q filed by SeqLL Inc.